Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

8

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Waterloo, ON (PRWEB) August 01, 2014 ... researchers has led to a better understanding embryonic ... differentiate and reorganize into structurally and functionally distinct ... devastating physical defects. Prof. Todd McDevitt, Melissa ... that biophysical signals interact with biochemical cues to ...
(Date:7/31/2014)... people over 60 are not donor candidates for bone ... time, making the elderly prone to life-threatening infection and ... now has discovered a reason why. , "We have ... blood-forming cells to maintain blood production over time in ... could be restored for rejuvenation therapies," said Emmanuelle Passegu, ...
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... ALBANY, New York , July 31, 2014 /PRNewswire/ ... published by Transparency Market Research "Electrodes for Medical Devices ... Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, ... Share, Growth, Trends and Forecast, 2013 - 2019," the ... USD 633.6 million in 2012 and is estimated to ...
Breaking Biology Technology:Study Links Biomechanics and Gene Expression in Stem Cells 2Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6
... Appointed -, CLINTON, N.J., Oct. 2 ... Kennedy as Senior Vice President,Engineering and Operations. In ... strategy and development., "Michael,s extensive experience will ... we continue to advance our pharmaceutical,pipeline through a ...
... DENVER, Oct. 2 Matthew B. Wiener, PharmD, ... the Outstanding,Cancer Leadership Award from the Colorado Cancer ... for his development of the Just-In-Time (JIT),enrollment methodology ... award on the evening of October 6th, at ...
... Epiphany Biosciences,Inc. announced today that Dr. Charles Sanders ... is a highly experienced biotechnology and,pharmaceutical executive, currently ... served as chief executive officer of Glaxo Inc., ... In addition, Dr. Sanders is also,a member of ...
Cached Biology Technology:Ikaria Strengthens Executive Leadership Team 2Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition 2
(Date:7/31/2014)... natural-gas production from shale rock has increased by ... still do not fully understand the industry,s effects ... in the journal Frontiers in Ecology and ... to vastly outpace scientific examination, a team of ... including Princeton University, concluded that determining the environmental ...
(Date:7/31/2014)... 3,000 genes to the earliest common ancestor of ... created an extensive "Tree of Lepidoptera" in the ... , Among the study,s more surprising findings: ... than to large ones, which completely changes scientists, ... found that some insects once classified as moths ...
(Date:7/31/2014)... shows the sustained efficacy, immunogenicity and safety ... Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted ... years, and vaccine efficacy (VE) against incident ... follow-up report for a licensed HPV vaccine. ... paper. , HPV and vaccination , ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... in Central Illinois are being exposed to polychlorinated biphenyls (PCBs) ... 1970s and ,80s. Their analysis appears in ... Illinois Department of Natural Resources collected 23 river otters between ... by cars or accidentally caught in traps, for example). The ...
... and other amphibians around the world releases a toxic ... investigators report Oct. 18 in the journal Science ... a long-standing puzzle why the amphibian immune system ... said Louise Rollins-Smith, Ph.D., associate professor of Pathology, Microbiology ...
... Oct. 10, 2013   DigitalPersona, Inc. , a ... announced the acquisition of Identity Stream, a leading ... identification of customers and employees in financial institutions.  ... Temenos, the banking software company, as T24 Biometrics.  ...
Cached Biology News:Illinois river otters exposed to chemicals banned decades ago 2Illinois river otters exposed to chemicals banned decades ago 3Frog-killing fungus paralyzes amphibian immune response 2DigitalPersona Expands Secure Banking Solutions Portfolio with Software Acquisition 2DigitalPersona Expands Secure Banking Solutions Portfolio with Software Acquisition 3
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... your lab productivity and allows you to achieve ... Move ahead beyond traditional paper-based weighing processes into ... *Instruments supported: ... XS, XP, PR, SR, PG-S, PG, SG, AT, ...
... ,Components g/500 ml: ,Tryptone ... chloride 2.5 ,Agar 6.0 ,S-Gal ... ,IPTG 0.025 ,Kanamycin 0.0175 ... complete growth medium containing S-Gal ...
Biology Products: